Janssen Signs Collaboration and License Agreement with Cellular Biomedicine to Develop CAR-T Therapies
By Lalit Mishra
Pharma Deals Review: Vol 2023 Issue 5 (Table of Contents)
Published: 18 May-2023
DOI: 10.3833/pdr.v2023.i5.2784 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In order to strengthen its chimeric antigen receptor (CAR)-T cell therapy portfolio, Janssen has entered into an agreement with Cellular Biomedicine to develop next-generation CAR-T cell therapies for treating B-cell malignancies...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS